Efficacy and safety of anlotinib maintenance therapy in limited-stage small cell lung cancer
Anlotinib as maintenance therapy significantly improved PFS and QoL in patients with LS-SCLC, with a manageable safety profile. This study provides initial evidence supporting the potential role of anlotinib in this treatment paradigm.
Authors
- Zhong‐Hua Chen (ORCID: https://orcid.org/0000-0002-7531-320X)
- Jie Lv
- Xiaohong Zhou (ORCID: https://orcid.org/0000-0002-5307-6709)
- Shaoping Li (ORCID: https://orcid.org/0000-0003-4255-6229)
Institutions
- Jiamusi University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1007/s12672-025-03895-0
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Commission of Heilongjiang Province